预约演示
更新于：2026-07-15
Benoxinate Hydrochloride
盐酸奥布卡因
更新于：2026-07-15
概要
基本信息
非在研机构- |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 日本 (1966-06-07), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C17H29ClN2O3 |
InChIKeyPRGUDWLMFLCODA-UHFFFAOYSA-N |
CAS号5987-82-6 |
关联
25
项与 盐酸奥布卡因 相关的临床试验ChiCTR2600120598
Effects of general anesthesia combined with oxybuprocaine hydrochloride eye drops on oculocardiac reflex, agitation and pain during recovery period during strabismus surgery in children
NCT07128979
Efficacy and Safety Evaluation of Ruscus Aculeatus L in Patients With Hemorrhoids: A Randomized, Double-blind Phase IV Clinical Trial
JPRN-UMIN000058188
Retinal blood flow testing for physiological load in healthy adults
100 项与 盐酸奥布卡因 相关的临床结果
登录后查看更多信息
100 项与 盐酸奥布卡因 相关的转化医学
登录后查看更多信息
100 项与 盐酸奥布卡因 相关的专利（医药）
登录后查看更多信息
409
项与 盐酸奥布卡因 相关的文献（医药）2026-09-01PSYCHIATRY RESEARCH-NEUROIMAGING
Brain white matter microstructural integrity differences between pre-post buprenorphine-naloxone treated individuals with opioid use disorder: Evidence from a DTI study
Article
作者: Nehra, Ritu ; Verma, Abhishek ; Ahuja, Chirag ; Govind, Varan ; Salan, Teddy ; Singh, Paramjit ; Kaur, Simranjit ; Modi, Manish ; Ghosh, Abhishek ; Basu, Debasish
Opioid use disorder (OUD) has been linked to alterations in brain white matter microstructure, but evidence comparing pre-treatment and six-month buprenorphine-naloxone (BNX) treatment remains limited. This study examined changes in brain diffusion tensor imaging (DTI) metrics before and after six months of BNX treatment in individuals with OUD and assessed the influence of concurrent cannabis and tobacco use. This pre-post study included 25 individuals with OUD initiating BNX treatment and 25 healthy controls. All participants underwent 3-Tesla brain DTI scans at baseline and at six-month follow-up. Fractional anisotropy (FA), mean diffusivity (MD), axial diffusivity (AD), and radial diffusivity (RD) were quantified across 48 regions of interests defined by JHU White Matter Atlas. Linear mixed-effects models were applied to examine group and time effects. At follow-up, the OUD group demonstrated widespread increases in MD, AD, RD compared with baseline and healthy controls, involving commissural, projection, and association tracts. Compared with healthy controls, the OUD group at baseline showed lower FA in key commissural and projection pathways. White matter changes after 6-month BNX treatment are modest overall but might be influenced by continued cannabis and tobacco use. Addressing concurrent substance use may be important for optimizing neurobiological recovery during buprenorphine treatment.
2026-05-01Eye & Contact Lens-Science and Clinical Practice
Benoxinate-Induced Keratopathy: Clinical Patterns and Management, a Cairo University Residents' Report
Article
作者: Hosny, Rawan ; Aboalazayem, Fayrouz ; Hosny, Mohamed ; Massoud, Maryam ; Saad, Maha ; Mostafa, Yehia Salah ; Shebl, Rana ; Yasser, Bassant ; Ashor, Ahmed Rashad
Purpose::
To describe clinical characteristics, patterns, and management options in benoxinate-induced keratopathy.
Methods::
Retrospective single-center study in which patients using benoxinate hydrochloride 0.4% for greater than 1 month and present with keratopathy and/or corneal complications were enrolled.
Results::
A total of 36 eyes were included, 90.5% belonged to welders. Median corrected distance visual acuity (CDVA) was 2.3 logMAR (hand motion). Secondary corneal abscess was present in 47.2% of eyes and 66.7% of eyes showed ring-shaped corneal deposits. Approximately 13.9% had corneal perforation at presentation and 22.3% had marked corneal thinning. All eyes except one had varying degrees of epithelial defects, mean defect 50.7±38.1 mm
2
. Approximately 47.2% received medical treatment and 52.7% were treated surgically. Size of epithelial defect was correlated to CDVA and presence of abscess (
P
=0.007 and 0.041). Choice of management was affected by size of epithelial defect and CDVA (
P
<0.001 and=0.006). CDVA did not improve after reepithelialization (
P
=0.157).
Conclusion::
Benoxinate-induced keratopathy is a potentially blinding and preventable disease. Stricter laws preventing over the counter availability is needed.
2026-05-01CORNEA
Diagnostic Eye Drops and Pain Sensitivity: A Marker for Dry Eye Syndrome?
Article
作者: Pereg, Avihu ; Mimouni, Michael ; Safir, Margarita ; Bahar, Irit ; Rock, Oded ; Holzman, Roie ; Gaton, Dan
Purpose::
The aim of this prospective study was to evaluate whether the duration and intensity of pain induced by commonly used diagnostic eye drops correlate with the presence and severity of dry eye syndrome.
Methods::
This study included 33 patients (66 eyes) undergoing routine evaluations at tertiary ophthalmology clinics from 2016 to 2017. Each eye received one drop of either oxybuprocaine or tropicamide. Pain intensity and duration were assessed using a visual analog scale and a stopwatch. Dry eye syndrome was diagnosed and graded according to international guidelines, incorporating clinical signs and standardized tests. Statistical analyses included Kruskal–Wallis tests for discrete variables and Pearson correlations for continuous variables, with significance set at
P
<0.05.
Results::
Patients with dry eye syndrome experienced significantly longer pain duration compared with those with healthy eyes (
P
= 0.035). Pain intensity was notably higher in patients with severe dry eye (
P
= 0.048). Duration of pain correlated with corneal fluorescein staining (
P
= 0.027). In eyes treated with oxybuprocaine, shorter tear break-up time and lower Schirmer test results were significantly associated with pain response (
P
= 0.021 and
P
= 0.037, respectively). In eyes treated with tropicamide, pain intensity was significantly associated with functional limitations (
P
= 0.042).
Conclusions::
This study highlights that pain sensitivity to commonly used diagnostic eye drops is a potential marker for the presence and severity of dry eye syndrome. Clinicians should consider evaluating pain responses during routine examinations as a simple, supplementary tool for identifying patients who may benefit from further diagnostic investigations and tailored management.
100 项与 盐酸奥布卡因 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 多泪 | 日本 | 1972-12-26 | |
| 麻醉 | 日本 | 1966-06-07 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 114 | Small incision lenticule extraction+Proxymetacaine 0.5%+Oxybuprocaine 0.4%+Tobramycin and dexamethasone+Ofloxacin | 選繭廠遞膚觸膚齋壓夢(願觸膚餘顧鑰餘範襯憲) = 蓋壓膚襯醖顧鬱淵夢鏇 願遞獵醖艱製築鬱蓋鑰 (蓋醖蓋膚淵艱製繭鹽衊, 0.48) 更多 | - | 2024-04-23 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
芽仔
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用